Literature DB >> 15105

Discriminative effects of morphine in the squirrel monkey.

G J Schaefer, S G Holzman.   

Abstract

Squirrel monkeys were trained in a two-choice discrete trial avoidance task to discriminate between intramuscular injections of saline and 3.0 mg/kg of morphine. Morphine (0.1-10 mg/kg) produced a dose-related increase in the number of trials completed on the morphine-appropriate lever. The stimulus control produced by the discriminative effects of morphine met the following criteria for classification as a specific narcotic effect: 1) morphine-like stimulus control was produced by all other narcotic analgesics tested (fentanyl, oxymorphone, levorphanol, methadone and meperidine); 2) in so doing, these drugs spanned a 900-fold potency range relative to morphine; 3) stimulus control was blocked by the specific narcotic antagonist naloxone; and 4) stereospecificity was a requirement for stimulus control--levorphanol produced stimulus control equivalent to 3.0 mg/kg of mrophine but its optical isomer dextrorphan did not. The time course of the stimulus control produced by 3.0 mg/kg of morphine showed that the animals continued to respond on the morphine-appropriate lever up to 14 hours after morphine administration. In contrast, monkeys administered 0.01 mg/kg of fentanyl responded on the morphine lever for only as lone as 1/2 hour after fentanyl administration. Naloxone, d-amphetamine and pentobarbital all failed to substitute for morphine, Thus, this study has extended previous observations of the discriminative properties of morphine in rats by demonstrating that qualitatively similar data are produced in a second species, the squirrel monkey.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 15105

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Morphine training dose: a determinant of stimulus generalization to narcotic antagonists in the rat.

Authors:  H E Shannon; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1979-03-28       Impact factor: 4.530

2.  Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Authors:  Carol A Paronis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-04       Impact factor: 4.030

3.  Dose- and time-dependent effects of narcotic analgesics on intracranial self-stimulation in the rat.

Authors:  G J Schaefer; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1977-08-16       Impact factor: 4.530

4.  Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; W Binstock; D W Coalson; T Cutter; D C Flemming; B Glosten
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey.

Authors:  David A White; Stephen G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  2003-03-18       Impact factor: 4.530

6.  Opioid agonist and antagonist behavioural effects of buprenorphine.

Authors:  J D Leander
Journal:  Br J Pharmacol       Date:  1983-04       Impact factor: 8.739

7.  Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey.

Authors:  S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Studies on the discriminative stimulus properties of ethanol in squirrel monkeys.

Authors:  J L York; R Bush
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  The discriminative stimulus properties and detection thresholds of intracranial self-stimulation: effects of d-amphetamine, morphine, and haloperidol.

Authors:  G J Schaefer; R P Michael
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Discriminative stimulus effects of etorphine in Rhesus monkeys.

Authors:  S Herling; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.